Metformin Hexal

Metformin Hydrochloride, the active ingredient in Metformin Hexal, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control. GNH USA supplies Metformin Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hexal, a biguanide antidiabetic, is used to manage hyperglycemia in type 2 diabetes and related insulin‑resistant conditions.

Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformin Hexal may cause a range of adverse reactions. Monitoring and reporting are essential for patient safety.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Metallic taste - Loss of appetite - Flatulence

Serious or Rare Side Effects: - Lactic acidosis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hypoglycemia when combined with other glucose‑lowering agents - Hepatic dysfunction - Pancreatitis - Anemia or hemolytic events

Before prescribing Metformin Hexal, clinicians should assess several safety factors. - Renal function: evaluate eGFR and avoid use in severe renal impairment. - Cardiovascular disease: monitor patients with heart failure for signs of lactic acidosis. - Lactic acidosis risk: avoid in conditions associated with hypoxia or severe infection. - Pregnancy and lactation: conduct a risk‑benefit assessment before use. - Drug interactions: review concomitant medications that may affect metformin levels. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Metformin Hexal can interact with various medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: increased risk of renal impairment and lactic acidosis. - Alcohol: potentiates lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Rifampin: reduces metformin efficacy. - Nucleoside reverse transcriptase inhibitors: heightened lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors/ARBs: watch for changes in kidney function. - NSAIDs: can affect renal clearance of metformin. - Thyroid hormones: may alter glucose metabolism.